This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundIntravenous thrombolysis (IVT) is an effective stroke therapy that remains underused. Outcomes included symptomatic intracranial hemorrhage, any intracranial hemorrhage, serious systemic bleeding, and 90‐day functional independence (modified Rankin scale score 0–2). The rates of symptomatic intracranial hemorrhage (3.4
The new analysis of the trial results, led by UVA Health’s Andrew Southerland , MD, found that high blood sugar shortly after thrombolysis – opening blocked arteries in the brain with a clot-busting drug – was associated with greater risk for potentially deadly brain bleeds, particularly in older patients with more severe strokes.
Introduction:Intravenous thrombolysis with alteplase (tPA) or tenecteplase (TNK) is a first-line treatment for acute ischemic stroke. The most serious risk associated with IV thrombolytics is symptomatic intracranial hemorrhage (sICH). sICH was defined as a hemorrhage that caused an increase in NIHSS by 4 or more points.
The safety of the treatment was evaluated based on the occurrence of any complications, the occurrence of intracerebral hemorrhage, and the occurrence of symptomatic intracerebral hemorrhage (assessed according to SITS-MOST criteria).Results:44 The incidence of intracerebral hemorrhage was 9.1% men, average age 71.512.2
One of the considered and currently increasingly preferred options is intravenous thrombolysis. Overall, intracerebral hemorrhage occurred in 6.3%. One patient had vitreous hemorrhage with subsequent correction of vision.Conclusion:CRAO is a significantly neglected subgroup of ischemic stroke.
Secondary endpoint included the radiographic pattern of hemorrhagic conversion according to the Heidelberg bleeding classification (HBC).Results:Median Suggested mechanisms of bleeding are hemorrhagic conversion in clinically silent infarcts and contusions underlying the lesions. Results:Median age was 62.94 for alteplase and 64.45
Background:Previous study found that compared with thrombolysis, antiplatelet did not improve outcomes but reduce the risk of symptomatic intracranial hemorrhage(sICH) for mild acute ischemic stroke(AIS) defined as National Institutes of Health Stroke Scale score 0 to 5. to 1.35]; mRS 0-2, odds ratio, 1.06 [95% CI, 0.73
BACKGROUND:Timely intravenous thrombolysis and endovascular thrombectomy are the standard reperfusion treatments for large vessel occlusion stroke. METHODS:We enrolled consecutive patients in the multicenter Taiwan Registry of Endovascular Thrombectomy for Acute Ischemic Stroke who had received combined thrombolysis (within 4.5
Introduction:Stroke is a leading cause of disability and mortality worldwide, with thrombolysis as a critical treatment. Studies aiming to assess the outcomes of thrombolysis after ischemic stroke in LMIC were selected. Seven randomized controlled trials (RCTs) were included and analyzed independently.
hour window, and reperfusion through thrombolysis has been shown to enhance functional outcomes in patients with salvageable brain tissue beyond this timeframe.Objective:The aim of this study is to assess the efficacy and safety of thrombolysis administered more than 4.5 These modalities can identify viable brain tissue beyond the 4.5-hour
Background:Cerebral amyloid angiopathy (CAA) is a hemorrhagic cerebrovascular disease that is thought to be due to excess protein deposition in vessel walls that lead to fragility and increase the risk of rupture. Stroke, Volume 56, Issue Suppl_1 , Page ADP1-ADP1, February 1, 2025. Primary outcome was routine discharge to home with self-care.
mg/kg]) comparing IVT with placebo or standard treatment from the EOS (Evaluation of Unknown-Onset Stroke Thrombolysis trial) data set. mg/kg]) comparing IVT with placebo or standard treatment from the EOS (Evaluation of Unknown-Onset Stroke Thrombolysis trial) data set. Death occurred in 4.0% and 0.3%, respectively (P=0.194).
Introduction:Current guidelines suggest using intravenous thrombolysis (IVT) for patients experiencing acute ischemic stroke within 4.5 The safety outcome was the rate of symptomatic intracranial hemorrhage (SICH).Results:We hours of symptom onset. Results:We included 79 patients (Table 1.) Twenty-two patients (27.8%) received IVT.
Safety outcomes were any intracerebral hemorrhage (ICH) and symptomatic ICH (sICH) at 24-36hrs. Background:Patients with acute ischemic stroke and a large vessel occlusion (LVO) admitted to primary stroke centers (PSC) often require inter-facility transfer for thrombectomy.
Introduction:The tenecteplase versus standard of care for minor ischemic stroke with proven occlusion (TEMPO-2) trial showed that patients presenting with minor deficits up to 12 h do not benefit from intravenous thrombolysis. h, if they were not eligible for standard-of-care thrombolysis. mg/kg) or non-thrombolytic standard of care.
Background and Aims:Machine learning models have shown promising potential for automated hemorrhage detection and segmentation, alleviating highly time-consuming manual contouring and facilitating rapid clinical diagnosis. The model had been trained upon a set of 331 CT scans with manually segmented parenchymal hemorrhage lesions.
The effectiveness and safety of intravenous thrombolysis (IVT) for acute ischemic stroke in these cases, particularly those involving large vessel occlusions, are debated. Stroke, Volume 56, Issue Suppl_1 , Page AWP9-AWP9, February 1, 2025. Background:Acute ischemic stroke can result from extracranial arterial dissection.
Intracerebral hemorrhage (ICH) is a main complication of IVT, with prevalence reported around 3.2% Additionally, extravasation of contrast was seen within the left basal ganglia region, concerning for hemorrhagic transformation from IV‐tPA. Left ICA stenting was not completed secondary to hemorrhagic transformation.
Contemporary treatments to remove the clot include intravenous thrombolysis or mechanical thrombectomy using a catheter. The rapid reperfusion that followed caused brain hemorrhage and increased mortality,” says Wegener. However, even with timely clot removal, many stroke patients only recover poorly.
However, there is conflicting data in terms of intracranial hemorrhage risk.Objective: We are reporting the rate of symptomatic intracranial hemorrhage(sICH) in TNK and tPA treated stroke populations across two large hospital systems.MethodsDesign: Retrospective cohort observational study.
Background and Aims:Endovascular treatment (EVT) alone has been confirmed to be non-inferior to intravenous thrombolysis (IVT) followed with EVT in acute ischemic stroke (AIS) due to large-vessel occlusion of the anterior circulation. Stroke, Volume 56, Issue Suppl_1 , Page AWP253-AWP253, February 1, 2025.
BACKGROUND:The effectiveness of intravenous thrombolysis (IVT) before endovascular treatment (EVT) has been investigated in randomized trials and meta-analyses. Although symptomatic intracranial hemorrhages occurred more often in the IVT group (4.8% Stroke, Ahead of Print. These studies mainly concerned anterior circulation occlusions.
We evaluated the risk of hemorrhage associated with newer, more potent antiplatelet medications and dual antiplatelet regimens among patients treated with intravenous tissue plasminogen activator (IV-tPA).Methods:Using The primary outcome of interest was symptomatic intracranial hemorrhage (sICH) within 36 hours of tPA administration.
Background and Aims:Previous studies indicated the usual dose heparin(5000 IU bolus followed by 500~1250 IU/h) during mechanical thrombectomy(MT) is associated with an increased risk of hemorrhagic conversion without beneficial effect. This trend also seemed to be seen in patients who did not undergo intravenous thrombolysis group.
Background:Symptomatic intracranial hemorrhage (sICH) is the most dreaded complication after reperfusion therapy for acute ischemic stroke. Concomitant use of intravenous thrombolysis and the use of MT in the extended therapeutic window do not raise the risk of sICH. 2.07; P = 0.037). 1.03; P = 0.079).
Background:The prognostic significance of the affected hemisphere in hemorrhagic stroke remains uncertain. We aimed to determine the relationship between the affected hemisphere (right or left) and differences in non-motor outcomes (pain, mood) in patients with acute intracerebral hemorrhage (ICH).
Introduction:Current guidelines recommend 24-hours of high-intensity monitoring (HIM) for acute ischemic stroke patients post-intravenous thrombolysis (IVT) due to risk of bleeding complications including symptomatic intracranial hemorrhage (sICH).
Direct-to-angiography workflow relies on CBCT to exclude intracranial hemorrhage (ICH) to determine treatment eligibility for intravenous thrombolysis (IVT) and/or mechanical thrombectomy (MT). Conclusion:CBCT had high specificity for ICH and hemorrhage types.
IntroductionEfficacy and safety of intravenous thrombolysis (IVT) in patients undergoing mechanical thrombectomy (MT) is still debatable. Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. However, IVT's efficacy on stent retriever (SR) and aspiration thrombectomy (ASP) outcomes specifically remain unclear.
Background:Intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are the standard of care for select stroke patients with acute large vessel occlusion (LVO). Fibrinogen levels may drop after IVT, and a significant decrease in fibrinogen is associated with an increased risk of intracranial hemorrhage (ICH).
We studied the impact of intravenous thrombolysis (IVT) on the outcomes of EVT in those patients.Methods:We conducted a meta-analysis using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist and the Cochrane Handbook of Systematic Reviews and Interventions.
Definitions of symptomatic HT developed during the intravenous thrombolysis (IVT) era are outdated in the endovascular thrombectomy (EVT) era but continue to be widely used. Symptomatic hemorrhages were due to subarachnoid hemorrhage in more than half and PH-2 in only one-quarter of symptomatic hemorrhages in this EVT series.
Background and objective:Perfusion imaging studies consistently show a substantially increased risk of hemorrhagic transformation (HT) in severely hypoperfused tissue. For this study, we included patients with some degree of recanalization (expanded Thrombolysis in Cerebral Infarct [eTICI] >0) and available baseline CT perfusion.
The role of adjunctive intravenous thrombolysis, such as intravenous tissue plasminogen activator (IVtPA), with MT remains unclear, especially for medium vessel occlusion (MeVO). Background:Mechanical thrombectomy (MT) has demonstrated superiority over medical therapy for acute ischemic stroke (AIS) with large vessel occlusion (LVO).
Recent landmark trials BEST-MSU and B_PROUD have proven that MSUs facilitate quicker thrombolysis times and improved functional outcomes at 90 days when compared to conventional emergency medical services (EMS) for acute ischemic stroke patients. Goal blood pressure was defined as systolic blood pressure <160.
Findings from the first international randomized controlled trial to compare patient outcomes following treatment with large-bore mechanical thrombectomy (LBMT) versus catheter-directed thrombolysis (CDT) for intermediate-risk pulmonary embolism (PE) show that LBMT is superior with respect to the hierarchically-tested aggregated outcome of all-cause (..)
Findings from the highly-anticipated MOST (Multi-Arm Optimization of Stroke Thrombolysis) trial were presented on the first day of the American Stroke Association’s International Stroke Conference, ISC 2024, being held through Feb. 9 Phoenix, AZ. Adeoye, M.D.,
Median time from the onset of visual change to thrombolysis was 6.0 [4.5-10.5] One (5.3%) patient had intra-ocular hemorrhage post thrombolysis.Conclusion:Compared to central retinal artery occlusion, patient with branched retinal occlusion have better visual recovery following IA or IV thrombolysis. VA improvement of ≥0.1
Introduction:Tenecteplase (TNK) is now an accepted alternative to Alteplase (ALT) for intravenous thrombolysis (IVT) in acute ischemic stroke (AIS). Hemorrhagic transformation (HT), a complication of IVT, is more frequent in acute hyperglycemia and diabetes (DM) and is associated with poor clinical outcomes.
Introduction:Collateral status imaging parameters are associated with predicting hemorrhagic transformation (HT) in acute ischemic stroke caused by large vessel occlusions. Stroke, Volume 55, Issue Suppl_1 , Page ATP146-ATP146, February 1, 2024.
Introduction:Outcomes after thrombolysis with alteplase (tPA) versus tenecteplase (TNK) prior to endovascular thrombectomy (EVT) have not been directly compared in real-world data (RWD). tPA was used exclusively for thrombolysis at one center (n=74), while TNK was used exclusively for thrombolysis at another center (n=130).
IntroductionThe risk of tandem occlusion treatment in the setting of intravenous thrombolysis is unclear. Patients who received thrombolysis and subsequently underwent endovascular therapy for acute ischemic stroke between 2012 and 2022 were included. Baseline demographics and clinical characteristics were compared.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content